N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide | 1550190-39-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide
• 英文别名: N-(2-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide；N-[2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]-4-(trifluoromethyl)benzenesulfonamide
• CAS: 1550190-39-0
• 化学式: C₁₉H₂₂BF₃N₂O₅S
• 分子量: 458.266
• InChiKey: HVFITNITUDGFDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.21
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  95.1
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide 、 7-溴-吡啶并[1,2-a]嘧啶-4-酮 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 3.0h， 生成 N-[2-methoxy-5-(4-oxopyrido[1,2-a]pyrimidin-7-yl)pyridin-3-yl]-4-(trifluoromethyl)benzenesulfonamide
  参考文献：
  名称：

  发现作为活性和口服活性双重抑制剂PI3K / mTOR的嘧啶并嘧啶酮

  摘要：

  一系列嘧啶嘧啶酮衍生物的鉴定和前导优化被描述为一类新型的有效PI3K / mTOR双重抑制剂，导致31的发现。化合物31在细胞分析中显示出对PI3K和mTOR的高酶活性，对Akt和p70s6k磷酸化的有效抑制作用，以及良好的药代动力学特征。此外，化合物31在PC-3M肿瘤异种移植模型中显示出体内功效。

  DOI：

  10.1021/acsmedchemlett.8b00002
• 作为产物：
  描述：

  3-氨基-5-溴-2-甲氧基吡啶 在 吡啶 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 反应 27.0h， 生成 N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-4-(trifluoromethyl)benzenesulfonamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors

  摘要：

  A novel series of 4-alkynyl-quinoline derivatives were designed, synthesized and biologically evaluated for their PI3K alpha inhibitory activities and anti-proliferative effects against two cancer cell lines PC-3 and HCT-116. Most of them showed potent PI3K alpha inhibitory activities with IC50 values at low nanomolar level and good to excellent anti-proliferative effects against both cell lines. Among them, compound 15d, the most potent one, was selected for further biological evaluation. As a result, 15d displayed strong inhibitory activity against other class I PI3K isoforms (PI3K beta, PI3K gamma and PI3K delta) and mTOR with an acceptable kinase selectivity profile. Moreover, the western blot assay indicated that the phosphorylation of Akt, another downstream effector of PI3K, can be remarkably suppressed by 15d at cellular level. All these experimental results suggested that 15d is a potent PI3K/mTOR dual inhibitor and could serve as a promising lead compound for the development of anticancer agents. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.05.025

文献信息

• Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
  作者：Ya’nan Yu、Yuqiao Han、Fupo Zhang、Zhenmei Gao、Tong Zhu、Suzhen Dong、Mingliang Ma

  DOI：10.1021/acs.jmedchem.9b01736

  日期：2020.3.26

  no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma

  PI3K-Akt-mTOR信号传导途径已被验证为癌症治疗的有效靶向途径。但是，尚未有FDA批准PI3K / mTOR双抑制剂。因此，寻找具有良好疗效和低毒性的候选药物仍然至关重要。在我们的设计中，已合成了一系列咪唑并[1,2-a]吡啶衍生物，并进行了体内和体外活性评估。15a被证明是一种有效的PI3K / mTOR双重抑制剂，具有出色的激酶选择性，适度的血浆清除率和可接受的口服生物利用度。此外，15a在HCT116和HT-29异种移植物中显示出对肿瘤生长的显着抑制作用，而对体重没有明显影响。
• Synthesis and structure–activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3- d ]pyrimidine derivatives
  作者：Fangbin Han、Songwen Lin、Peng Liu、Jing Tao、Chongqin Yi、Heng Xu

  DOI：10.1016/j.bmcl.2014.07.073

  日期：2014.9

  inhibitors provides a promising new approach to the treatment of cancers. In this Letter, we identified structurally novel and potent PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives. Their synthesis and structure–activity relationships are reported.

  PI3K / mTOR双重抑制剂抑制磷酸肌醇3激酶（PI3K）/ AKT /哺乳动物对雷帕霉素（mTOR）信号通路的靶标，为癌症的治疗提供了一种有希望的新方法。在这封信中，我们从一系列的2-氨基-4-甲基吡啶并[2,3- d ]嘧啶衍生物中鉴定了结构新颖且有效的PI3K / mTOR双重抑制剂。报告了它们的合成和结构-活性关系。
• Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors
  作者：Songwen Lin、Fangbin Han、Peng Liu、Jing Tao、Xuechao Zhong、Xiujie Liu、Chongqin Yi、Heng Xu

  DOI：10.1016/j.bmcl.2013.12.112

  日期：2014.2

  Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin ( mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors. Design, synthesis and structure activity relationship are reported. (C) 2013 Elsevier Ltd. All rights reserved.
• Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors
  作者：Fangbin Han、Songwen Lin、Peng Liu、Xiujie Liu、Jing Tao、Xiaobing Deng、Chongqin Yi、Heng Xu

  DOI：10.1021/ml5005014

  日期：2015.4.9

  Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway provides a promising new approach for cancer therapy. Through a rational design, a novel series of thienopyrimidine was discovered as highly potent and selective PI3K inhibitors. These thienopyrimidine derivatives were demonstrated to bear nanomolar PI3K alpha inhibitory potency with over 100-fold selectivity against mTOR kinase. The lead compounds 6g and 6k showed good developability profiles in cell-based proliferation and ADME assays. In this communication, their design, synthesis, structure activity relationship, selectivity, and some developability properties are described.
• Discovery of a series of N -(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors
  作者：Jiankang Zhang、Xiaoqing Lv、Xiaodong Ma、Yongzhou Hu

  DOI：10.1016/j.ejmech.2017.01.016

  日期：2017.2

  Recently, the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) have been considered as promising targets for the treatment of cancer. Herein, we synthesized a series of N-(5(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as novel PI3K/mTOR dual inhibitors for cancer therapy. In the biological evaluation, compound 17e was identified as a potent PI3K/mTOR dual inhibitor, which significantly inhibit Class I PI3Ks, mTOR and phosphorylation of pAkt(Ser473) at low nanomolar level. Moreover, 17e display high potency against PC-3 cells (IC50 = 80 nM) in the anti-proliferative assay, and showed acceptable pharmacokinetic properties in vivo. (c) 2017 Elsevier Masson SAS. All rights reserved.